美康生物 (300439.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.5B	1.5B	1.7B	1.9B	2.5B
Cost of Revenue	978.8M	972.7M	966.1M	1.1B	1.5B
Gross Profit	562.3M	566.4M	776.3M	832.2M	949.6M
Operating Expenses
R&D Expense	120.2M	127.2M	146.5M	149.8M	171.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	173.4M	173.2M	165.9M	187.0M	174.8M
Selling & Marketing Expense	226.0M	225.5M	237.2M	253.6M	300.4M
Other Expenses	—	—	—	—	—
Total Operating Expenses	539.0M	544.2M	559.8M	607.8M	667.1M
Cost and Expenses	1.5B	1.5B	1.5B	1.7B	2.2B
Operating Income (EBIT)	36.9M	33.3M	267.5M	279.1M	228.6M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	50.0M	46.1M	282.4M	295.7M	223.3M
Income Tax Expense	(14.8M)	(15.3M)	19.7M	36.2M	18.1M
Bottom Line
Net Income	66.6M	63.2M	258.0M	256.6M	198.5M
Earnings from Cont. Ops	64.8M	61.4M	262.7M	259.5M	205.2M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	66.6M	63.2M	258.0M	256.6M	198.5M
Per Share
Basic EPS	CN¥0.18	CN¥0.16	CN¥0.67	CN¥0.67	CN¥0.52
Diluted EPS	CN¥0.18	CN¥0.16	CN¥0.67	CN¥0.67	CN¥0.52
Revenue Per Share	CN¥4.11	CN¥3.90	CN¥4.52	CN¥4.93	CN¥6.52
Shares
Basic Shares Outstanding	375.2M	395.0M	385.1M	382.9M	381.8M
Diluted Shares Outstanding	375.2M	395.0M	385.1M	382.9M	381.8M
Profitability Metrics
EBITDA	—	204.2M	474.4M	447.0M	418.7M
D&A	—	170.9M	206.8M	167.9M	190.1M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026